

11783251

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	9	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	10	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	11	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	12	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	13	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	14	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	15	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	16	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	17	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	18	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

11783251

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:50:11 ON 11 JAN 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:50:20 ON 11 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JAN 2007 HIGHEST RN 917201-58-2

DICTIONARY FILE UPDATES: 10 JAN 2007 HIGHEST RN 917201-58-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d 11



NO L# DEFINED

There are no L# queries, structures, or screen sets defined in the current session.

=>

Uploading C:\Program Files\Stnexp\Queries\10783251.str

11783251



chain nodes :
17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
1-10 2-17
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-2 1-5 1-10 2-3 2-17 3-4 4-5 4-6 5-9 6-7 7-8 8-9
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :


G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR

11783251



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

SAMPLE SEARCH INITIATED 18:50:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 158 TO ITERATE

100.0% PROCESSED 158 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2406 TO 3914

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> d l2 ibib

'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties

11783251

EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):0
'0' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

11783251

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.


The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):ide

11783251

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 752259-62-4 REGISTRY
ED Entered STN: 27 Sep 2004
CN Imidazo[1,2-a]pyrimidine, 2-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)
MF C19 H14 N4 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

11783251

=>

Uploading C:\Program Files\Stnexp\Queries\10783251a.str



chain nodes :

13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 15 16 17 18

chain bonds :

1-6 2-13

ring bonds :

1-2 1-5 2-3 3-4 3-15 4-5 4-18 6-7 6-11 7-8 8-9 9-10 10-11 15-16 16-17 17-18

exact/norm bonds :

1-2 1-5 1-6 2-3 2-13 3-4 3-15 4-5 4-18 15-16 16-17 17-18

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 :

G1:C,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 13:Atom 15:Atom 16:Atom 17:Atom 18:Atom


L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR

11783251



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sam

SAMPLE SEARCH INITIATED 18:53:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 156 TO ITERATE

100.0% PROCESSED 156 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2371 TO 3869

PROJECTED ANSWERS: 11 TO 389

L4 10 SEA SSS SAM L3

=> s l3 and l1 full

FULL SEARCH INITIATED 18:53:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3313 TO ITERATE

100.0% PROCESSED 3313 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L3 AND L1

=> s l1 full

FULL SEARCH INITIATED 18:53:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3387 TO ITERATE

100.0% PROCESSED 3387 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

L6 8 SEA SSS FUL L1

11783251

=> s 13 full

FULL SEARCH INITIATED 18:53:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3338 TO ITERATE

100.0% PROCESSED 3338 ITERATIONS

345 ANSWERS

SEARCH TIME: 00.00.01

L7 345 SEA SSS FUL L3

=> s 16 and 17

L8 0 L6 AND L7

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

520.05

520.26

FILE 'CAPLUS' ENTERED AT 18:54:41 ON 11 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jan 2007 VOL 146 ISS 3

FILE LAST UPDATED: 10 Jan 2007 (20070110/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 16 and 17

3 L6

7 L7

L9 1 L6 AND L7

=> s 16

L10 3 L6


=> s 17

L11 7 L7

=> d l10 ibib hitstr abs 1-3

11783251

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:693020 CAPLUS
DOCUMENT NUMBER: 145:314934
TITLE: Efficient Pd(0)-Mediated Microwave-Assisted Arylation
of 2-Substituted Imidazo[1,2-a]pyrimidines
AUTHOR(S): Ermolat'ev, D. S.; Gimenez, V. N.; Babaev, E. V.; Van
der Eycken, E.
CORPORATE SOURCE: Laboratory for Organic and Microwave-Assisted
Chemistry (LOMAC), Department of Chemistry, University
of Leuven, Louvain, B-3001, Belg.
SOURCE: Journal of Combinatorial Chemistry (2006), 8(5),
659-663
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 909104-10-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2,3-substituted imidazo[1,2-a]pyrimidines by Pd(0)-mediated
microwave-assisted Heck-type arylation of 2-substituted
imidazo[1,2-a]pyrimidines with aryl bromides)
RN 909104-10-5 CAPLUS
CN Imidazo[1,2-a]pyrimidine, 2-phenyl-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



AB A short and practical synthesis of 2,3-substituted imidazo[1,2-a]pyrimidines, based on microwave-assisted Heck-type arylation of 2-substituted imidazo[1,2-a]pyrimidines, was developed. A 45-membered library of 2,3-substituted imidazo[1,2-a]pyrimidines was obtained with good yields and purities using this optimized protocol.
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

11783251

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:739973 CAPLUS

DOCUMENT NUMBER: 141:243552

TITLE: Preparation of heteroaromatic fused imidazole derivatives as transforming growth factor (TGF) inhibitors

INVENTOR(S): Blumberg, Laura C.; Munchhof, Michael J.; Shavnya, Andrei

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 2004176390	A1	20040909	US 2004-783251	20040220
CA 2517933	A1	20040916	CA 2004-2517933	20040223
WO 2004078110	A2	20040916	WO 2004-IB532	20040223
WO 2004078110	A3	20041111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1601676	A2	20051207	EP 2004-713609	20040223
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007999	A	20060307	BR 2004-7999	20040223
JP 2006519249	T	20060824	JP 2006-506271	20040223
NL 1025623	A1	20040907	NL 2004-1025623	20040303
NL 1025623	C2	20050314		
PRIORITY APPLN. INFO.:			US 2003-451683P	P 20030304
			WO 2004-IB532	W 20040223

OTHER SOURCE(S): MARPAT 141:243552

IT 752259-62-4P 752259-64-6P 752259-65-7P

752259-68-0P 752259-69-1P 752259-76-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarom. fused imidazole derivs. as transforming growth factor (TGF) inhibitors)

RN 752259-62-4 CAPLUS


CN Imidazo[1,2-a]pyrimidine, 2-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 752259-64-6 CAPLUS

CN Imidazo[1,2-b]pyridazine, 2-(1,3-benzodioxol-5-yl)-6-chloro-3-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 752259-65-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 752259-68-0 CAPLUS


CN Quinoline, 6-[3-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)

11783251




RN 752259-69-1 CAPLUS

CN Quinoline, 6-[3-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-2-yl]- (9CI)
(CA INDEX NAME)



RN 752259-76-0 CAPLUS

CN 1H-Benzotriazole, 1-methyl-6-[3-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I and II [R1 = optionally substituted (un)saturated or aromatic mono-, bi, or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O, and S, such as pyridinyl, benzotriazolyl, quinolinyl, etc. ; R2 = H, halo, haloalkyl, alkyl, alkenyl, alkynyl, etc.; s = 1-5; R3 and R4 taken together with the atoms

to which they are attached form a core fused heteroarom, such as imidazopyrimidinyl, imidazopyridinyl, imidazopyrimidinyl, etc.] were prepared as potent inhibitors of transforming growth factor ("TGF")- β signaling pathway for the treatment of various TGF-related disease states including cancer and fibrotic diseases. For example, compound III was prepared in a multi-step synthesis starting from benzo[1,3]dioxole-5-carboxylic acid. In in vitro β 1-transforming growth factors kinase assay, compound IV exhibited an IC₅₀ value of 253 nM.

11783251

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:94933 CAPLUS

DOCUMENT NUMBER: 110:94933

TITLE: Condensation of α -(hetaryl)-2,4-dioxyacetophenones with iodine and heterocyclic nitrogen bases

AUTHOR(S): Kalitka, V. V.; Khilya, V. P.; Proshakova, E. V.

CORPORATE SOURCE: Melitopol. Pedagog. Inst., Melilopol, USSR

SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition) (1988), 54(2), 199-203

CODEN: UKZHAU; ISSN: 0041-6045

DOCUMENT TYPE: Journal

LANGUAGE: Russian


OTHER SOURCE(S): CASREACT 110:94933

IT 118082-35-2P


RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 118082-35-2 CAPLUS

CN 1,3-Benzenediol, 4-[3-(2-pyridinyl)imidazo[1,2-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)



GI



AB Condensation of acetophenones I ($R = H, 4\text{-MeOC}_6\text{H}_4, 2\text{-benzofuranyl}, 4\text{-thiazolyl}, 2\text{-methyl-4-thiazolyl}, 2\text{-pyridyl}$, $R_1 = M, Et$) with pyridines II ($R_2 = 2\text{-}, 3\text{-}, 4\text{-Me}, 2\text{-H}_2\text{N}$) and iodine in polar solvents gave 38-78%

11783251

pyridinium iodides III. Addnl. obtained were 19-23% pyrrolopyridines IV
(R as above, R1 = H, Et).

11783251

=> d 111 ibib hitstr abs 1-7

11783251

L11 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:386432 CAPLUS

DOCUMENT NUMBER: 144:425692

TITLE: Methods using TGF- β type I receptor inhibitors
and Alk4 inhibitors for treating vascular injuries
INVENTOR(S): Ling, Leona E.; Fu, Kai; Gill, Alan; Gotwals, Philip
J.

PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA

SOURCE: PCT Int. Appl., 228 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2006044509	A2	20060427	WO 2005-US36770	20051013
WO 2006044509	A3	20060817		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-619116P P 20041015

OTHER SOURCE(S): MARPAT 144:425692

IT 673480-82-5 673480-88-1 673480-90-5
673480-92-7 673480-95-0 673481-00-0
673481-03-3 673481-06-6 673481-09-9
673481-12-4 673481-14-6 673481-17-9
673481-20-4 673481-23-7 673481-25-9
673481-28-2 673481-30-6 673481-33-9
673481-37-3 673481-39-5 673481-41-9
673481-43-1 673481-45-3 673481-48-6
673481-54-4 673481-57-7 673481-59-9
673481-62-4 673481-65-7 673481-68-0
673481-71-5 673481-74-8 673481-77-1
673481-81-7 673481-83-9 673481-85-1
673481-88-4 673481-91-9 673481-95-3
673482-01-4 673482-03-6 673482-08-1
673482-09-2 673482-15-0 673482-17-2
673482-20-7 673482-23-0 673482-25-2
673482-28-5 673482-30-9 673482-32-1
673482-35-4 673482-37-6 673482-40-1
673482-43-4 673482-46-7 673482-49-0
673482-52-5 673482-55-8 673482-57-0
673482-59-2 673482-61-6 673482-63-8
673482-67-2 673482-69-4 673482-72-9
673482-74-1 673482-76-3 673482-80-9
673482-82-1 673482-84-3 673482-86-5


11783251

673482-88-7 673482-90-1 673482-93-4
673482-95-6 673482-97-8 673483-00-6
673483-04-0 673483-07-3 673483-11-9
673483-14-2 673483-17-5 673483-20-0
673483-27-7 673483-30-2 673483-34-6
673483-37-9 673483-40-4 673483-44-8
673483-47-1 673483-49-3 673483-51-7
673483-53-9 673483-56-2 673483-60-8
673483-64-2 673483-66-4 673483-68-6
673483-71-1 673483-73-3 673483-75-5
673483-78-8 673483-80-2 673483-82-4
673483-85-7 673483-88-0 673483-90-4
673483-92-6 673483-94-8 673483-96-0
673483-98-2 673484-02-1 673484-04-3
673484-06-5 673484-08-7 673484-10-1
673484-12-3 673484-14-5 673484-16-7
673484-18-9 673484-20-3 673484-22-5
673484-24-7 673484-26-9 673484-28-1
673484-30-5 673484-32-7 673484-34-9
673484-36-1 673484-38-3 673484-40-7
673484-42-9 673484-44-1 673484-50-9 67348
4-52-1 673484-55-4 673484-57-6
673484-59-8 673484-61-2 673484-95-2
673485-00-2 673485-01-3 673485-76-2
673501-80-9 884595-86-2 884595-87-3

RL: DEV (Device component use); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(TGF- β type I receptor inhibitors and Alk4 inhibitors for treating
vascular injuries)

RN 673480-82-5 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673480-88-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)


11783251




RN 673480-90-5 CAPLUS
CN 2-Pyrimidinamine, N-[(4-methoxyphenyl)methyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673480-92-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673480-95-0 CAPLUS
CN Imidazo[1,2-a]pyrimidin-7-amine, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673481-00-0 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-03-3 CAPLUS

CN 2-Pyrimidinamine, N-[(4-aminophenyl)methyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-06-6 CAPLUS

CN 4-Morpholineethanamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673481-09-9 CAPLUS


CN 1,2-Ethanediamine, N,N-dimethyl-N'-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673481-12-4 CAPLUS


CN Acetamide, N-[2-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-14-6 CAPLUS

CN Acetamide, N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 673481-17-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 673481-20-4 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 673481-23-7 CAPLUS


CN Carbamic acid, [4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

11783251




RN 673481-25-9 CAPLUS

CN 1,4-Butanediamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673481-28-2 CAPLUS

CN Carbamic acid, [3-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 673481-30-6 CAPLUS


CN 1,3-Propanediamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673481-33-9 CAPLUS


CN 4-Morpholinepropanamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-37-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 673481-39-5 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 673481-41-9 CAPLUS


CN 2-Pyrimidinamine, N-methyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673481-43-1 CAPLUS


CN 2-Pyrimidinamine, N,N-dimethyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-45-3 CAPLUS

CN 2-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-48-6 CAPLUS

CN Phenol, 3-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 673481-54-4 CAPLUS


CN Carbamic acid, [5-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 673481-57-7 CAPLUS


CN 2-Pyrimidinamine, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-59-9 CAPLUS

CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-62-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673481-65-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673481-68-0 CAPLUS


CN 2-Pyrimidinamine, N-(2-methoxyethyl)-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-71-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673481-74-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(2-methyl-1-aziridinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673481-77-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 673481-81-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1H-tetrazol-5-yl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-83-9 CAPLUS

CN 2-Pyrimidinecarbonitrile, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-85-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(1-azetidiny)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673481-88-4 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-91-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-

11783251

[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 673481-95-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 673482-01-4 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-03-6 CAPLUS

CN 2-Pyrimidinamine, 4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673482-08-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673482-09-2 CAPLUS


CN 2-Pyrimidinamine, 4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-15-0 CAPLUS


11783251

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673482-17-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-chloro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-20-7 CAPLUS


CN Imidazo[1,2-a]pyridine-6-methanol, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673482-23-0 CAPLUS


CN Imidazo[1,2-a]pyridine-6-methanol, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-25-2 CAPLUS

CN Imidazo[1,2-a]pyridine-6-methanol, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-28-5 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 673482-30-9 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)

11783251




RN 673482-32-1 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 673482-35-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-37-6 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



11783251


RN 673482-40-1 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-ethyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673482-43-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-46-7 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(2-methoxyethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-49-0 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(1,4-dioxan-2-ylmethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 673482-52-5 CAPLUS

CN β-Alanine, N-[[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-6-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 673482-55-8 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 673482-57-0 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-59-2 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-cyclopropyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-61-6 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-(4-morpholinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-63-8 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[8-bromo-6-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-67-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(3-pyridinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-69-4 CAPLUS

CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(2-pyridinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673482-72-9 CAPLUS

CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(4-


11783251

pyridinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-74-1 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(4-morpholinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-76-3 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-80-9 CAPLUS

CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 673482-82-1 CAPLUS


CN 2-Pyrimidinamine, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-(4-morpholinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-84-3 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

11783251



RN 673482-86-5 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 673482-88-7 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-90-1 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 673482-93-4 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 673482-95-6 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)

11783251




RN 673482-97-8 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673483-00-6 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 673483-04-0 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-cyclopropyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-07-3 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

11783251




RN 673483-11-9 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-ethyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673483-14-2 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-17-5 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, N-(2-aminoethyl)-3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-20-0 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)

11783251




RN 673483-27-7 CAPLUS

CN β -Alanine, N-[[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-7-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 673483-30-2 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(1,4-dioxan-2-ylmethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-34-6 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(2-hydroxyethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 673483-37-9 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673483-40-4 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-oxo-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 673483-44-8 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-hydroxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-47-1 CAPLUS


CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673483-49-3 CAPLUS

CN 3-Pyridinepropanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673483-51-7 CAPLUS

CN 3-Pyridinepropanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-53-9 CAPLUS


CN 3-Pyridinepropanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-56-2 CAPLUS


CN Benzeneacetamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-3-methoxy- (9CI) (CA INDEX NAME)

11783251




RN 673483-60-8 CAPLUS

CN Benzeneacetamide, 3-methoxy-N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-64-2 CAPLUS


CN Propanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673483-66-4 CAPLUS

CN Propanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)


11783251




RN 673483-68-6 CAPLUS
CN Propanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-71-1 CAPLUS
CN Butanamide, 3,3-dimethyl-N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673483-73-3 CAPLUS
CN Butanamide, 3,3-dimethyl-N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-75-5 CAPLUS


11783251

CN Butanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 673483-78-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673483-80-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-82-4 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



11783251


RN 673483-85-7 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 673483-88-0 CAPLUS

CN Imidazo[1,2-a]pyridine-7-methanol, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673483-90-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-methyl-1-piperidinyl)propyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673483-92-6 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



11783251

RN 673483-94-8 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 673483-96-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 673483-98-2 CAPLUS


CN 2H-Pyrano[3,2-g]quinoline-6-methanesulfonic acid, 8,9-dihydro-8,8-dimethyl-9-[6-[[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]-6-oxohexyl]-2-oxo-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

11783251


PAGE 1-A



PAGE 2-A




RN 673484-02-1 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(4-pyrimidinyl)- (9CI)
(CA INDEX NAME)




RN 673484-04-3 CAPLUS
CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 673484-06-5 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carbonitrile, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673484-08-7 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673484-10-1 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 673484-12-3 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-hydroxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673484-14-5 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carbonitrile, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673484-16-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



11783251


RN 673484-18-9 CAPLUS

CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-6-carboxamide,
2',4,4',5',7,7'-hexachloro-3',6'-dihydroxy-N-[4-[[4-[2-(6-methyl-2-
pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-3-oxo-
(9CI) (CA INDEX NAME)




RN 673484-20-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)



RN 673484-22-5 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(6-chloro-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)



RN 673484-24-7 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673484-26-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673484-28-1 CAPLUS

CN 2-Pyrimidinamine, 4-[6-bromo-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-30-5 CAPLUS


CN 2-Pyrimidinamine, 4-[6-fluoro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-32-7 CAPLUS


CN 2-Pyrimidinamine, 4-[6-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673484-34-9 CAPLUS

CN Imidazo[1,2-a]pyridine-7-methanamine, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673484-36-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-[2-(6-methyl-2-pyridinyl)-8-(phenylmethoxy)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-38-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)-8-(phenylmethoxy)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673484-40-7 CAPLUS

CN 1-Naphthalenesulfonamide, 5-(dimethylamino)-N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]- (9CI)


11783251

(CA INDEX NAME)




RN 673484-42-9 CAPLUS

CN Spiro[isobenzofuran-1(3H), 9'-[9H]xanthene]-5-carboxamide, 2',7'-difluoro-3',6'-dihydroxy-N-[4-[[4-[2-(6-methyl-2-pyridinyl)]imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-3-oxo- (9CI) (CA INDEX NAME)



RN 673484-44-1 CAPLUS


CN Xanthylum, 3,6-diamino-9-[2-carboxy-5-[[[4-[[4-[2-(6-methyl-2-pyridinyl)]imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]carbonyl]phenyl]-, inner salt (9CI) (CA INDEX NAME)



RN 673484-50-9 CAPLUS


CN 2H-1-Benzopyran-6-sulfonic acid, 7-amino-4-methyl-3-[2-[[4-[[4-[2-(6-methyl-2-pyridinyl)]imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]-2-oxoethyl]-2-oxo- (9CI) (CA INDEX NAME)

11783251




RN 673484-52-1 CAPLUS

CN 2-Pyrimidinamine, N-cyclobutyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-55-4 CAPLUS

CN 2-Pyrimidinamine, N-(1-methylethyl)-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673484-57-6 CAPLUS


CN 1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j']diquinolizin-18-ium, 2,3,6,7,12,13,16,17-octahydro-9-[4-[[[6-[[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]-6-oxohexyl]amino]sulfonyl]-2-sulfophenyl]-, inner salt (9CI) (CA INDEX NAME)

11783251

PAGE 1-A




PAGE 2-A




RN 673484-59-8 CAPLUS
CN Acetamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673484-61-2 CAPLUS

CN Acetamide, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673484-95-2 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673485-00-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-bromo-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673485-01-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-fluoro-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251



RN 673485-76-2 CAPLUS


CN 2-Pyrimidinamine, N-(cyclopropylmethyl)-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673501-80-9 CAPLUS

CN Boron, [5-[(3,5-dimethyl-2H-pyrrol-2-ylidene)methyl]-N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-1H-pyrrole-2-propanamidato-κN1]difluoro-, (T-4)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 884595-86-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N- (9CI) (CA INDEX NAME)

11783251


1,3,4-thiadiazol-2-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 884595-87-3 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, 2,2-dimethylhydrazide (9CI) (CA INDEX NAME)



AB The invention discloses the use of TGF- β type I receptor inhibitors and Alk4 inhibitors and implantable devices including these compds. in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).

11783251

L11 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1310699 CAPLUS

DOCUMENT NUMBER: 144:36343

TITLE: Preparation of imidazopyridines and their use as activin receptor-like kinase 5 (ALK5) inhibitors for treatment of TGF β -related diseases

INVENTOR(S): Sato, Masakazu; Matsunaga, Yuiko; Asanuma, Hajime

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 35 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005343889	A	20051215	JP 2005-128778	20050427
PRIORITY APPLN. INFO.:			JP 2004-137544	A 20040506

OTHER SOURCE(S): MARPAT 144:36343


IT 870990-74-2P 870990-75-3P 870990-76-4P
870990-77-5P 870990-78-6P 870990-79-7P
870990-80-0P 870990-81-1P 870990-82-2P
870990-83-3P 870990-84-4P 870990-85-5P
870990-86-6P 870990-87-7P 870990-88-8P
870990-89-9P 870990-90-2P 870990-91-3P
870990-92-4P 870990-93-5P 870990-94-6P
870990-95-7P 870990-96-8P 870990-97-9P
870990-98-0P 870990-99-1P 870991-00-7P
870991-01-8P 870991-02-9P 870991-06-3P
870991-22-3P 870991-23-4P

RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridines as activin receptor-like kinase 5 inhibitors for treatment of TGF β -related diseases)

RN 870990-74-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(4-methoxyphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-75-3 CAPLUS


CN Phenol, 4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 870990-76-4 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(4-methoxyphenyl)-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 870990-77-5 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(4-methoxyphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-78-6 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(4-methoxyphenyl)-N-propyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-79-7 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(4-hydroxyphenyl)-N-propyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 870990-80-0 CAPLUS

CN Imidazo[1,2-a]pyridine-7-methanol, 3-(4-methoxyphenyl)-2-(2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 870990-81-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-(azidomethyl)-3-(4-methoxyphenyl)-2-(2-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-82-2 CAPLUS


CN Imidazo[1,2-a]pyridine-7-methanamine, 3-(4-methoxyphenyl)-2-(2-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 870990-83-3 CAPLUS


CN Butanamide, N-[[3-(4-methoxyphenyl)-2-(2-pyridinyl)imidazo[1,2-a]pyridin-7-
yl]methyl]- (9CI) (CA INDEX NAME)

11783251




RN 870990-84-4 CAPLUS

CN Butanamide, N-[[3-(4-hydroxyphenyl)-2-(2-pyridinyl)imidazo[1,2-a]pyridin-7-yl]methyl]- (9CI) (CA INDEX NAME)




RN 870990-85-5 CAPLUS

CN Carbamic acid, [3-(4-methoxyphenyl)-2-(2-pyridinyl)imidazo[1,2-a]pyridin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 870990-86-6 CAPLUS


CN Imidazo[1,2-a]pyridin-7-amine, 3-(4-methoxyphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-87-7 CAPLUS


CN Butanamide, N-[3-(4-methoxyphenyl)-2-(2-pyridinyl)imidazo[1,2-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)

11783251




RN 870990-88-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 870990-89-9 CAPLUS

CN Phenol, 4-[7-methyl-2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 870990-90-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(4-methoxyphenyl)-8-(phenylmethoxy)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-91-3 CAPLUS


CN Imidazo[1,2-a]pyridin-8-ol, 3-(4-methoxyphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 870990-92-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-(phenylmethoxy)-3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 870990-93-5 CAPLUS

CN Imidazo[1,2-a]pyridin-8-ol, 3-(4-hydroxyphenyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-94-6 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-fluoro-3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-95-7 CAPLUS


CN Phenol, 4-[6-fluoro-2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 870990-96-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-nitro-3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 870990-97-9 CAPLUS

CN Imidazo[1,2-a]pyridin-6-amine, 3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870990-98-0 CAPLUS


CN Butanamide, N-[3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)imidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 870990-99-1 CAPLUS


CN Butanamide, N-[3-(4-hydroxyphenyl)-2-(2-pyridinyl)imidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)

11783251




RN 870991-00-7 CAPLUS

CN Phenol, 4-[6-amino-2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 870991-01-8 CAPLUS

CN Imidazo[1,2-a]pyridine-6-methanol, 3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 870991-02-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-(azidomethyl)-3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 870991-06-3 CAPLUS

CN Phenol, 4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

11783251


CM 1

CRN 870990-75-3
CMF C18 H13 N3 O




CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 870991-22-3 CAPLUS
CN Imidazo[1,2-a]pyridine-6-methanamine, 3-[4-(phenylmethoxy)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 870991-23-4 CAPLUS
CN Phenol, 4-[6-(aminomethyl)-2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251



GI



AB Title compds. I [R1 = Ph substituted with halo, C1-6 alkyl(oxy), arylalkoxy, OH; (hetero)cycllyl-condensed benzene ring; R2 = (un)substituted 2-pyridyl, (un)substituted 2- or 4-thiazolyl] or their medically acceptable salts are prepared They are useful for treatment of alopecia, diabetic renal disease, cirrhosis, etc. Thus, cyclocondensation of 2-bromo-2-(4-methoxyphenyl)-1-pyridin-2-ylethanone with 2-aminopyridine gave 3-(4-methoxyphenyl)-2-pyridin-2-ylimidazo[1,2-a]pyridine, which was demethylated to afford phenol derivative The product inhibited TGF- β 1-induced phosphorylation of Smad2/3.

11783251

L11 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:739973 CAPLUS

DOCUMENT NUMBER: 141:243552

TITLE: Preparation of heteroaromatic fused imidazole derivatives as transforming growth factor (TGF) inhibitors

INVENTOR(S): Blumberg, Laura C.; Munchhof, Michael J.; Shavnya, Andrei

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 2004176390	A1	20040909	US 2004-783251	20040220
CA 2517933	A1	20040916	CA 2004-2517933	20040223
WO 2004078110	A2	20040916	WO 2004-IB532	20040223
WO 2004078110	A3	20041111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1601676	A2	20051207	EP 2004-713609	20040223
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007999	A	20060307	BR 2004-7999	20040223
JP 2006519249	T	20060824	JP 2006-506271	20040223
NL 1025623	A1	20040907	NL 2004-1025623	20040303
NL 1025623	C2	20050314		

PRIORITY APPLN. INFO.: US 2003-451683P P 20030304
WO 2004-IB532 W 20040223

OTHER SOURCE(S): MARPAT 141:243552

IT 752259-66-8P 752259-67-9P 752259-72-6P
752259-73-7P 752259-74-8P 752259-77-1P
752259-80-6P 752259-81-7P 752259-82-8P
752259-83-9P 752259-86-2P 752259-87-3P
752259-90-8P 752259-92-0P 752259-95-3P
752259-96-4P 752259-97-5P 752259-98-6P
752260-00-7P 752260-01-8P 752260-04-1P
752260-05-2P 752260-06-3P 752260-09-6P
752260-10-9P 752260-11-0P 752260-14-3P
752260-15-4P 752260-16-5P 752260-19-8P
752260-20-1P 752260-21-2P 752260-24-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarom. fused imidazole derivs. as transforming growth factor (TGF) inhibitors)

RN 752259-66-8 CAPLUS


11783251

CN Quinoline, 6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]- (9CI)
(CA INDEX NAME)




RN 752259-67-9 CAPLUS

CN Quinoline, 6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrazin-3-yl]- (9CI)
(CA INDEX NAME)




RN 752259-72-6 CAPLUS

CN Quinoline, 6-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)



RN 752259-73-7 CAPLUS

CN Quinoline, 6-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 752259-74-8 CAPLUS

CN Quinoline, 6-[6-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-


11783251

(9CI) (CA INDEX NAME)




RN 752259-77-1 CAPLUS

CN 1H-Benzotriazole, 1-methyl-6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 752259-80-6 CAPLUS

CN Quinoline, 6-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 752259-81-7 CAPLUS


CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 752259-82-8 CAPLUS


11783251

CN Quinoline, 6-[7-methyl-2-(6-methyl-2-pyridinyl)-6-nitroimidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 752259-83-9 CAPLUS

CN 1H-Benzotriazole, 1-methyl-6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 752259-86-2 CAPLUS


CN 2H-Benzotriazole, 2-methyl-5-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 752259-87-3 CAPLUS


CN Imidazo[1,2-a]pyrimidin-7-amine, 3-(2-methyl-2H-benzotriazol-5-yl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 752259-90-8 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7(1H)-one, 2-(6-methyl-2-pyridinyl)-3-(6-quinolinyl)- (9CI) (CA INDEX NAME)




RN 752259-92-0 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, N,N-dimethyl-2-(6-methyl-2-pyridinyl)-3-(6-quinolinyl)- (9CI) (CA INDEX NAME)



RN 752259-95-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 752259-96-4 CAPLUS


CN Imidazo[1,2-a]pyrimidine, 2-(6-methyl-2-pyridinyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 752259-97-5 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 752259-98-6 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 3-(6-benzothiazolyl)-2-(6-methyl-2-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 752260-00-7 CAPLUS


CN Quinoxaline, 6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]-
(9CI) (CA INDEX NAME)



RN 752260-01-8 CAPLUS


11783251

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(6-quinoxaliny)- (9CI) (CA INDEX NAME)




RN 752260-04-1 CAPLUS

CN Quinoxaline, 6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 752260-05-2 CAPLUS


CN 1,5-Naphthyridine, 2-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 752260-06-3 CAPLUS


CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(1,5-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)

11783251




RN 752260-09-6 CAPLUS

CN 1,5-Naphthyridine, 2-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 752260-10-9 CAPLUS

CN Imidazo[1,2-a]pyrimidine, 3-(1,2-dimethyl-1H-benzimidazol-6-yl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 752260-11-0 CAPLUS


CN Imidazo[1,2-a]pyrimidin-7-amine, 3-(3a,7a-dihydro-1,2-dimethyl-1H-benzimidazol-6-yl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 752260-14-3 CAPLUS


11783251

CN 1H-Benzimidazole, 1,2-dimethyl-6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 752260-15-4 CAPLUS

CN Imidazo[1,2-a]pyrimidine, 3-(2-methyl-6-benzoxazolyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 752260-16-5 CAPLUS


CN Imidazo[1,2-a]pyrimidin-7-amine, 3-(3a,7a-dihydro-2-methyl-6-benzoxazolyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 752260-19-8 CAPLUS


CN Benzoxazole, 2-methyl-6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 752260-20-1 CAPLUS

CN Quinazoline, 6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]-
(9CI) (CA INDEX NAME)




RN 752260-21-2 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(6-
quinazolinyl)- (9CI) (CA INDEX NAME)



RN 752260-24-5 CAPLUS

CN Quinazoline, 6-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-3-yl]- (9CI)
(CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I and II [R1 = optionally substituted (un)saturated or aromatic

mono-, bi, or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O, and S, such as pyridinyl, benzotriazolyl, quinolinyl, etc. ; R2 = H, halo, haloalkyl, alkyl, alkenyl, alkynyl, etc.; s = 1-5; R3 and R4 taken together with the atoms to which they are attached form a core fused heteroarom, such as imidazopyrimidinyl, imidazopyridinyl, imidazopyrimidinyl, etc.] were prepared as potent inhibitors of transforming growth factor ("TGF")- β signaling pathway for the treatment of various TGF-related disease states including cancer and fibrotic diseases. For example, compound III was prepared in a multi-step synthesis starting from benzo[1,3]dioxole-5-carboxylic acid. In in vitro β 1-transforming growth factors kinase assay, compound IV exhibited an IC50 value of 253 nM.

L11 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:220155 CAPLUS

DOCUMENT NUMBER: 140:270866

TITLE: Preparation of (pyridinyl)(pyrimidinyl)imidazo[1,2-a]pyridines as TGF β receptor type I antagonists for treatment of fibrotic disorders and tumors

INVENTOR(S): Lee, Wen-cherng; Carter, Mary Beth; Sun, Lihong; Chuaqui, Claudio; Singh, Juswinder; Boriack-Sjodin, Paula; Choi, Michael S.

PATENT ASSIGNEE(S): Biogen, Inc., USA

SOURCE: PCT Int. Appl., 142 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004021989	A2	20040318	WO 2003-US27721	20030905
WO 2004021989	A3	20040923		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2497968	A1	20040318	CA 2003-2497968	20030905
AU 2003270318	A1	20040329	AU 2003-270318	20030905
EP 1546112	A2	20050629	EP 2003-752004	20030905
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014052	A	20050705	BR 2003-14052	20030905
CN 1694871	A	20051109	CN 2003-824866	20030905
JP 2006502164	T	20060119	JP 2004-534570	20030905
NZ 539068	A	20061027	NZ 2003-539068	20030905
ZA 2005001863	A	20050913	ZA 2005-1853	20050303
NO 2005001493	A	20050321	NO 2005-1493	20050321
US 2006135517	A1	20060622	US 2005-526653	20051101
PRIORITY APPLN. INFO.:			US 2002-408812P	P 20020906
			WO 2003-US27721	W 20030905

OTHER SOURCE(S): MARPAT 140:270866


IT 673480-82-5P 673480-88-1P 673480-90-5P
 673481-23-7P 673481-28-2P 673481-83-9P
 673481-99-7P 673482-01-4P 673482-06-9P
 673482-08-1P 673482-12-7P 673482-15-0P
 673482-20-7P 673482-23-0P 673482-28-5P
 673482-30-9P 673482-35-4P 673482-63-8P
 673482-90-1P 673482-93-4P 673482-95-6P
 673482-97-8P 673483-47-1P 673483-49-3P
 673483-51-7P 673483-58-4P 673483-60-8P
 673483-64-2P 673483-66-4P 673483-71-1P
 673483-73-3P 673483-78-8P 673483-80-2P

11783251

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (pyridinyl)(pyrimidinyl)imidazo[1,2-a]pyridines as TGF β receptor type I antagonists for treatment of fibrotic disorders and tumors)


RN 673480-82-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673480-88-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673480-90-5 CAPLUS


CN 2-Pyrimidinamine, N-[(4-methoxyphenyl)methyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673481-23-7 CAPLUS


CN Carbamic acid, [4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

11783251




RN 673481-28-2 CAPLUS

CN Carbamic acid, [3-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 673481-83-9 CAPLUS

CN 2-Pyrimidinecarbonitrile, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673481-99-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673482-01-4 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-06-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673482-08-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673482-12-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673482-15-0 CAPLUS


11783251

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673482-20-7 CAPLUS

CN Imidazo[1,2-a]pyridine-6-methanol, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673482-23-0 CAPLUS


CN Imidazo[1,2-a]pyridine-6-methanol, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673482-28-5 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)

11783251




RN 673482-30-9 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 673482-35-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-63-8 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[8-bromo-6-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



11783251


RN 673482-90-1 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 673482-93-4 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 673482-95-6 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 673482-97-8 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



11783251


RN 673483-47-1 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673483-49-3 CAPLUS

CN 3-Pyridinepropanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-51-7 CAPLUS


CN 3-Pyridinepropanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-58-4 CAPLUS


CN Benzeneacetamide, 3-methoxy-N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673483-60-8 CAPLUS

CN Benzeneacetamide, 3-methoxy-N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-64-2 CAPLUS


CN Propanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-66-4 CAPLUS


CN Propanamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673483-71-1 CAPLUS

CN Butanamide, 3,3-dimethyl-N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673483-73-3 CAPLUS

CN Butanamide, 3,3-dimethyl-N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-78-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-80-2 CAPLUS

11783251

CN 3-Pyridinecarboxamide, N-[2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



IT 673480-92-7P 673480-93-8P 673480-95-0P
673480-96-1P 673481-00-0P 673481-01-1P
673481-03-3P 673481-04-4P 673481-06-6P
673481-07-7P 673481-09-9P 673481-10-2P
673481-12-4P 673481-14-6P 673481-15-7P
673481-17-9P 673481-18-0P 673481-20-4P
673481-21-5P 673481-25-9P 673481-26-0P
673481-30-6P 673481-31-7P 673481-33-9P
673481-34-0P 673481-37-3P 673481-39-5P
673481-41-9P 673481-43-1P 673481-45-3P
673481-46-4P 673481-48-6P 673481-49-7P
673481-51-1P 673481-52-2P 673481-54-4P
673481-55-5P 673481-57-7P 673481-59-9P
673481-60-2P 673481-62-4P 673481-63-5P
673481-65-7P 673481-66-8P 673481-68-0P
673481-69-1P 673481-71-5P 673481-72-6P
673481-74-8P 673481-75-9P 673481-77-1P
673481-78-2P 673481-81-7P 673481-85-1P
673481-86-2P 673481-88-4P 673481-89-5P
673481-91-9P 673481-92-0P 673481-95-3P
673481-96-4P 673482-03-6P 673482-04-7P
673482-10-5P 673482-17-2P 673482-18-3P
673482-25-2P 673482-26-3P 673482-32-1P
673482-33-2P 673482-37-6P 673482-38-7P
673482-40-1P 673482-41-2P 673482-43-4P
673482-44-5P 673482-46-7P 673482-47-8P
673482-49-0P 673482-50-3P 673482-52-5P
673482-53-6P 673482-55-8P 673482-57-0P
673482-59-2P 673482-61-6P 673482-67-2P
673482-69-4P 673482-72-9P 673482-74-1P
673482-76-3P 673482-80-9P 673482-82-1P
673482-84-3P 673482-86-5P 673482-88-7P
673482-98-9P 673483-00-6P 673483-01-7P
673483-04-0P 673483-05-1P 673483-07-3P
673483-08-4P 673483-11-9P 673483-12-0P
673483-14-2P 673483-15-3P 673483-17-5P
673483-18-6P 673483-20-0P 673483-21-1P
673483-24-4P 673483-25-5P 673483-27-7P
673483-28-8P 673483-30-2P 673483-31-3P
673483-34-6P 673483-35-7P 673483-37-9P
673483-38-0P 673483-40-4P 673483-41-5P
673483-44-8P 673483-45-9P 673483-53-9P

11783251


673483-54-0P 673483-56-2P 673483-62-0P
673483-68-6P 673483-69-7P 673483-75-5P
673483-76-6P 673483-82-4P 673483-83-5P
673483-85-7P 673483-86-8P 673483-88-0P
673483-90-4P 673483-92-6P 673483-94-8P
673483-96-0P 673483-98-2P 673484-00-9P
673484-02-1P 673484-04-3P 673484-06-5P
673484-08-7P 673484-10-1P 673484-12-3P
673484-14-5P 673484-16-7P 673484-18-9P
673484-20-3P 673484-22-5P 673484-24-7P
673484-26-9P 673484-28-1P 673484-30-5P
673484-32-7P 673484-34-9P 673484-36-1P
673484-38-3P 673484-40-7P 673484-42-9P
673484-44-1P 673484-46-3P 673484-48-5P
673484-50-9P 673484-52-1P 673484-55-4P
673484-57-6P 673484-59-8P 673484-61-2P
673484-95-2P 673485-00-2P 673485-01-3P
673485-76-2P 673501-80-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (pyridinyl)(pyrimidinyl)imidazo[1,2-a]pyridines as TGF β receptor type I antagonists for treatment of fibrotic disorders and tumors)

RN 673480-92-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 673480-93-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673480-92-7


CMF C17 H14 N6




11783251

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 673480-95-0 CAPLUS
CN Imidazo[1,2-a]pyrimidin-7-amine, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673480-96-1 CAPLUS
CN Imidazo[1,2-a]pyrimidin-7-amine, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 673480-95-0
CMF C16 H14 N8



CM 2


CRN 76-05-1
CMF C2 H F3 O2

11783251



RN 673481-00-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673481-01-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-00-0


CMF C21 H20 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 673481-03-3 CAPLUS

CN 2-Pyrimidinamine, N-[(4-aminophenyl)methyl]-4-[2-(6-methyl-2-

11783251

pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-04-4 CAPLUS

CN 2-Pyrimidinamine, N-[(4-aminophenyl)methyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-03-3


CMF C24 H21 N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673481-06-6 CAPLUS

CN 4-Morpholineethanamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-07-7 CAPLUS

CN 4-Morpholineethanamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-06-6


CMF C23 H25 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673481-09-9 CAPLUS

CN 1,2-Ethanediamine, N,N-dimethyl-N'-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




11783251

RN 673481-10-2 CAPLUS
CN 1,2-Ethanediamine, N,N-dimethyl-N'-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 673481-09-9
CMF C21 H23 N7




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 673481-12-4 CAPLUS
CN Acetamide, N-[2-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 673481-14-6 CAPLUS
CN Acetamide, N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]- (9CI) (CA INDEX NAME)

11783251




RN 673481-15-7 CAPLUS

CN Acetamide, N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-14-6


CMF C23 H25 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673481-17-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




11783251

RN 673481-18-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(3-pyridinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-17-9


CMF C24 H21 N7




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 673481-20-4 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 673481-21-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(4-pyridinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-20-4

CMF C24 H21 N7


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673481-25-9 CAPLUS

CN 1,4-Butanediamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673481-26-0 CAPLUS

CN 1,4-Butanediamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-25-9

CMF C21 H23 N7




11783251

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673481-30-6 CAPLUS

CN 1,3-Propanediamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673481-31-7 CAPLUS

CN 1,3-Propanediamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-30-6

CMF C20 H21 N7




CM 2

CRN 76-05-1


CMF C2 H F3 O2

11783251



RN 673481-33-9 CAPLUS

CN 4-Morpholinepropanamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673481-34-0 CAPLUS

CN 4-Morpholinepropanamine, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-33-9


CMF C24 H27 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673481-37-3 CAPLUS


11783251

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 673481-39-5 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 673481-41-9 CAPLUS

CN 2-Pyrimidinamine, N-methyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673481-43-1 CAPLUS


CN 2-Pyrimidinamine, N,N-dimethyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673481-45-3 CAPLUS

11783251

CN 2-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-46-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-45-3


CMF C23 H22 N8



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673481-48-6 CAPLUS

CN Phenol, 3-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


11783251



RN 673481-49-7 CAPLUS
CN Phenol, 3-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 673481-48-6
CMF C23 H18 N6 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 673481-51-1 CAPLUS
CN 1,3,4-Thiadiazol-2-amine, 5-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)


11783251



RN 673481-52-2 CAPLUS
CN 1,3,4-Thiadiazol-2-amine, 5-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 673481-51-1
CMF C19 H14 N8 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 673481-54-4 CAPLUS
CN Carbamic acid, [5-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

11783251




RN 673481-55-5 CAPLUS

CN Carbamic acid, [5-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]pentyl]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-54-4


CMF C27 H33 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673481-57-7 CAPLUS


CN 2-Pyrimidinamine, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



11783251

RN 673481-59-9 CAPLUS

CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-60-2 CAPLUS

CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-59-9


CMF C20 H18 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673481-62-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


11783251



RN 673481-63-5 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 673481-62-4
CMF C21 H20 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 673481-65-7 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1-piperidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




11783251

RN 673481-66-8 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1-piperidinyl)-4-pyrimidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 673481-65-7
CMF C22 H22 N6




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 673481-68-0 CAPLUS
CN 2-Pyrimidinamine, N-(2-methoxyethyl)-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673481-69-1 CAPLUS
CN 2-Pyrimidinamine, N-(2-methoxyethyl)-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-68-0
CMF C20 H20 N6 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673481-71-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673481-72-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methyl-1-piperazinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-71-5


CMF C22 H23 N7




11783251

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 673481-74-8 CAPLUS
CN Imidazo[1,2-a]pyridine, 3-[2-(2-methyl-1-aziridinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673481-75-9 CAPLUS
CN Imidazo[1,2-a]pyridine, 3-[2-(2-methyl-1-aziridinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 673481-74-8
CMF C20 H18 N6



CM 2


CRN 76-05-1
CMF C2 H F3 O2

11783251



RN 673481-77-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 673481-78-2 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-1H-pyrazol-3-yl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-77-1

CMF C20 H16 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2

11783251




RN 673481-81-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-(1H-tetrazol-5-yl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673481-85-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(1-azetidinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673481-86-2 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(1-azetidinyl)-4-pyrimidinyl]-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-85-1


CMF C20 H18 N6




11783251

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 673481-88-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673481-89-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 673481-88-4
CMF C22 H22 N6



CM 2

CRN 76-05-1
CMF C2 H F3 O2


11783251



RN 673481-91-9 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 673481-92-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[(1S)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 673481-91-9

CMF C25 H22 N6

Absolute stereochemistry.


11783251



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 673481-95-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

11783251



RN 673481-96-4 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[(1R)-1-phenylethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673481-95-3

CMF C25 H22 N6

Absolute stereochemistry.




CM 2

CRN 76-05-1


CMF C2 H F3 O2

11783251



RN 673482-03-6 CAPLUS

CN 2-Pyrimidinamine, 4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673482-04-7 CAPLUS

CN 2-Pyrimidinamine, 4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-03-6


CMF C18 H16 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 673482-10-5 CAPLUS


11783251

CN 2-Pyrimidinamine, 4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-09-2


CMF C18 H16 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-17-2 CAPLUS

CN 2-Pyrimidinamine, 4-[6-chloro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-18-3 CAPLUS


CN 2-Pyrimidinamine, 4-[6-chloro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-17-2

CMF C17 H13 Cl N6


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-25-2 CAPLUS

CN Imidazo[1,2-a]pyridine-6-methanol, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-26-3 CAPLUS


CN Imidazo[1,2-a]pyridine-6-methanol, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-25-2

CMF C18 H16 N6 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-32-1 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 673482-33-2 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-32-1

CMF C19 H16 N6 O2


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-37-6 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-38-7 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-37-6

CMF C19 H17 N7 O2


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-40-1 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-ethyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-41-2 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-ethyl-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-40-1

CMF C20 H19 N7 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-43-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-44-5 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-43-4

CMF C22 H24 N8 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-46-7 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(2-methoxyethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-47-8 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(2-methoxyethyl)-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-46-7

CMF C21 H21 N7 O2


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-49-0 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(1,4-dioxan-2-ylmethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-50-3 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(1,4-dioxan-2-ylmethyl)-2-(6-methyl-2-pyridinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-49-0

CMF C23 H23 N7 O3


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-52-5 CAPLUS

CN β -Alanine, N-[[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-6-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 673482-53-6 CAPLUS


CN β -Alanine, N-[[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-6-yl]carbonyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-52-5

CMF C22 H21 N7 O3


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673482-55-8 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(methanesulfonyl)- (9CI) (CA INDEX NAME)



RN 673482-57-0 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-59-2 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-cyclopropyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673482-61-6 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-(4-morpholinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-67-2 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(3-pyridinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251



RN 673482-69-4 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(2-pyridinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-72-9 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(4-pyridinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251



RN 673482-74-1 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-[[2-(4-morpholinyl)ethyl]amino]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-76-3 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-80-9 CAPLUS

CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 673482-82-1 CAPLUS


CN 2-Pyrimidinamine, 4-[6-methyl-2-(6-methyl-2-pyridinyl)-8-(4-morpholinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673482-84-3 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

11783251



RN 673482-86-5 CAPLUS


CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 673482-88-7 CAPLUS

CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-6-methyl-2-(6-methyl-2-pyridinyl)-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

11783251




RN 673482-98-9 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673482-97-8


CMF C18 H14 N6 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673483-00-6 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

11783251




RN 673483-01-7 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(methylsulfonyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-00-6


CMF C19 H17 N7 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-04-0 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-cyclopropyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




11783251

RN 673483-05-1 CAPLUS
CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-cyclopropyl-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 673483-04-0
CMF C21 H19 N7 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 673483-07-3 CAPLUS
CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 673483-08-4 CAPLUS
CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-(2-thienyl)ethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-07-3

11783251


CMF C24 H21 N7 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-11-9 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-ethyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-12-0 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-ethyl-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-11-9

CMF C20 H19 N7 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-14-2 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673483-15-3 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-14-2


CMF C19 H17 N7 O2




11783251

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 673483-17-5 CAPLUS
CN Imidazo[1,2-a]pyridine-7-carboxamide, N-(2-aminoethyl)-3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-18-6 CAPLUS
CN Imidazo[1,2-a]pyridine-7-carboxamide, N-(2-aminoethyl)-3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 673483-17-5
CMF C20 H20 N8 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2

11783251



RN 673483-20-0 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 673483-21-1 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-(3-piperidinylmethyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-20-0


CMF C24 H26 N8 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673483-24-4 CAPLUS

11783251

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, hydrazide (9CI) (CA INDEX NAME)




RN 673483-25-5 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxylic acid, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-, hydrazide, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-24-4


CMF C18 H16 N8 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673483-27-7 CAPLUS

CN β -Alanine, N-[[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-7-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

11783251




RN 673483-28-8 CAPLUS

CN β -Alanine, N-[[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-7-yl]carbonyl]-, methyl ester, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-27-7


CMF C22 H21 N7 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673483-30-2 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(1,4-dioxan-2-ylmethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251



11783251

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(2-hydroxyethyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673483-35-7 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-(2-hydroxyethyl)-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-34-6


CMF C20 H19 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 673483-37-9 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 673483-38-0 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-37-9


CMF C22 H24 N8 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-40-4 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-oxo-2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



11783251


RN 673483-41-5 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)-N-[2-oxo-2-(3-pyridinyl)ethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-40-4


CMF C25 H20 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-44-8 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-hydroxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673483-45-9 CAPLUS


CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-hydroxy-2-(6-methyl-2-pyridinyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-44-8

11783251


CMF C18 H15 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-53-9 CAPLUS

CN 3-Pyridinepropanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-54-0 CAPLUS


CN 3-Pyridinepropanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-53-9

CMF C24 H21 N9 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-56-2 CAPLUS

CN Benzeneacetamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 673483-62-0 CAPLUS


CN Benzeneacetamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-3-methoxy-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-56-2

CMF C25 H22 N8 O2


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-68-6 CAPLUS

CN Propanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 673483-69-7 CAPLUS


CN Propanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-68-6

CMF C19 H18 N8 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-75-5 CAPLUS

CN Butanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 673483-76-6 CAPLUS


CN Butanamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-3,3-dimethyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-75-5

CMF C22 H24 N8 O


11783251



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-82-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 673483-83-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-82-4

CMF C22 H17 N9 O




11783251

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 673483-85-7 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 673483-86-8 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-(4-pyrimidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 673483-85-7

CMF C16 H13 N7




CM 2

CRN 76-05-1


CMF C2 H F3 O2

11783251




RN 673483-88-0 CAPLUS

CN Imidazo[1,2-a]pyridine-7-methanol, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673483-90-4 CAPLUS

CN 2-Pyrimidinamine, N-[3-(4-methyl-1-piperidiny)propyl]-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673483-92-6 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 673483-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)


11783251



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 673483-96-0 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 673483-98-2 CAPLUS


CN 2H-Pyrano[3,2-g]quinoline-6-methanesulfonic acid, 8,9-dihydro-8,8-dimethyl-9-[6-[[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]-6-oxohexyl]-2-oxo-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

11783251

PAGE 1-A




PAGE 2-A




RN 673484-00-9 CAPLUS
CN Acetamide, N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-2-[(2',4,5,7,7'-pentafluoro-3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-6-yl)thio]-(9CI) (CA INDEX NAME)

11783251




RN 673484-02-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(4-pyrimidinyl)- (9CI)
(CA INDEX NAME)




RN 673484-04-3 CAPLUS

CN Imidazo[1,2-a]pyridin-8-amine, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673484-06-5 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carbonitrile, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673484-08-7 CAPLUS


11783251

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-[3-(4-methyl-1-piperazinyl)propyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673484-10-1 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673484-12-3 CAPLUS


CN Imidazo[1,2-a]pyridine-6-carboxamide, 3-(2-amino-4-pyrimidinyl)-N-hydroxy-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 673484-14-5 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carbonitrile, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


11783251



RN 673484-16-7 CAPLUS
CN Imidazo[1,2-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 673484-18-9 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-6-carboxamide,
2',4,4',5',7,7'-hexachloro-3',6'-dihydroxy-N-[4-[[4-[2-(6-methyl-2-
pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-3-oxo-
(9CI) (CA INDEX NAME)




RN 673484-20-3 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)

11783251




RN 673484-22-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-chloro-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 673484-24-7 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)-7-
(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-26-9 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-
3-yl]- (9CI) (CA INDEX NAME)



RN 673484-28-1 CAPLUS


CN 2-Pyrimidinamine, 4-[6-bromo-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-
3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673484-30-5 CAPLUS

CN 2-Pyrimidinamine, 4-[6-fluoro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673484-32-7 CAPLUS

CN 2-Pyrimidinamine, 4-[6-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-34-9 CAPLUS


CN Imidazo[1,2-a]pyridine-7-methanamine, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673484-36-1 CAPLUS


CN 2(1H)-Pyrimidinone, 4-[2-(6-methyl-2-pyridinyl)-8-(phenylmethoxy)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673484-38-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)-8-(phenylmethoxy)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-40-7 CAPLUS


CN 1-Naphthalenesulfonamide, 5-(dimethylamino)-N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]- (9CI) (CA INDEX NAME)



RN 673484-42-9 CAPLUS


CN Spiro[isobenzofuran-1(3H), 9'-[9H]xanthene]-5-carboxamide, 2',7'-difluoro-3',6'-dihydroxy-N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-3-oxo- (9CI) (CA INDEX NAME)

11783251




RN 673484-44-1 CAPLUS

CN Xanthylum, 3,6-diamino-9-[2-carboxy-5-[[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]carboxyl]phenyl]-, inner salt (9CI) (CA INDEX NAME)



RN 673484-46-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 5-bromo-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673484-48-5 CAPLUS


CN Imidazo[1,2-a]pyridine, 5-fluoro-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251




RN 673484-50-9 CAPLUS

CN 2H-1-Benzopyran-6-sulfonic acid, 7-amino-4-methyl-3-[2-[[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]-2-oxoethyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 673484-52-1 CAPLUS

CN 2-Pyrimidinamine, N-cyclobutyl-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 673484-55-4 CAPLUS


CN 2-Pyrimidinamine, N-(1-methylethyl)-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




11783251

RN 673484-57-6 CAPLUS
CN 1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j']diquinolizin-18-ium,
2,3,6,7,12,13,16,17-octahydro-9-[4-[[[6-[[4-[[4-[2-(6-methyl-2-
pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]amino]-6-
oxohexyl]amino]sulfonyl]-2-sulfophenyl]-, inner salt (9CI) (CA INDEX
NAME)

PAGE 1-A




PAGE 2-A




RN 673484-59-8 CAPLUS
CN Acetamide, N-[3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-
pyridinyl)imidazo[1,2-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

11783251




RN 673484-61-2 CAPLUS

CN Acetamide, N-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673484-95-2 CAPLUS

CN Imidazo[1,2-a]pyridine-7-carboxamide, 3-(2-amino-4-pyrimidinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 673485-00-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-bromo-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 673485-01-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-fluoro-2-(6-methyl-2-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

11783251



RN 673485-76-2 CAPLUS


CN 2-Pyrimidinamine, N-(cyclopropylmethyl)-4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 673501-80-9 CAPLUS

CN Boron, [5-[(3,5-dimethyl-2H-pyrrol-2-ylidene)methyl]-N-[4-[[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]butyl]-1H-pyrrole-2-propanamidato-κN1]difluoro-, (T-4)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




IT 673480-98-3 673482-65-0 673482-78-5

11783251

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (pyridinyl)(pyrimidinyl)imidazo[1,2-a]pyridines as TGF β receptor type I antagonists for treatment of fibrotic disorders and tumors)


RN 673480-98-3 CAPLUS

CN Imidazo[1,2-a]pyrimidin-7-amine, 2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673482-65-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-bromo-6-methyl-2-(6-methyl-2-pyridinyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 673482-78-5 CAPLUS

CN 2-Pyrimidinamine, 4-[8-bromo-6-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [wherein X_1 , X_2 , X_3 , X_4 = independently CR_x or N, only two of them can be N simultaneously; Y_1 , Y_2 = independently CR_a or N, at least one of them must be N; R_1 = independently alkyl, alkenyl, alkynyl, alkoxy, acyl, urea, cycloalkylsulfanyl, etc.; R_2 = independently alkyl, alkenyl, alkynyl, acyl, halo, $-N(alkyl)(cycloalkyl)$, heteroaroyl, etc.; $m = 0-4$; $n = 0-3$; R_x , R_a = independently hydrogen, alkyl, alkenyl, hydroxy, guanidino, amidino, cycloalkylcarbonylamino, etc.; and pharmaceutically acceptable salts or N-oxides thereof] were prepared as antagonists against transforming growth factor β ($TGF\beta$) family type I receptors, $Alk5$ and $Alk4$. For example, methylation of 2-mercapto-4-methylpyrimidine with MeI, followed by reaction with 6-methylpyridine-2-carboxylic acid Et ester and cyclocondensation with 2-aminopyridine, gave II. I exhibited $TGF\beta$ -induced PAI-Luciferase reporter activity with IC_{50} values of less than $10\mu M$ and cytotoxicity with LD_{25} values greater than $10\mu M$. Thus, I and their pharmaceutical compns. are useful as antagonists for preventing and/or treating numerous diseases, including fibrotic disorders and tumors.

11783251

L11 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:120853 CAPLUS

DOCUMENT NUMBER: 140:163875

TITLE: Preparation of imidazopyridines as inhibitors of the transforming growth factor-beta (TGF- β) signalling pathway

INVENTOR(S): Dodic, Nerina; Gellibert, Francoise Jeanne

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013138	A2	20040212	WO 2003-EP8390	20030729
WO 2004013138	A3	20040325		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003255323	A1	20040223	AU 2003-255323	20030729
EP 1543003	A2	20050622	EP 2003-766355	20030729
EP 1543003	B1	20060517		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005537291	T	20051208	JP 2004-525375	20030729
AT 326467	T	20060615	AT 2003-766355	20030729
ES 2259419	T3	20061001	ES 2003-3766355	20030729
US 2005234029	A1	20051020	US 2005-522967	20050131
PRIORITY APPLN. INFO.:			GB 2002-17783	A 20020731
			WO 2003-EP8390	W 20030729

OTHER SOURCE(S): MARPAT 140:163875

IT 656239-73-5P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-74-6P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-75-7P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-trifluoromethoxyphenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-76-8P, 3-[2-(4-Cyanophenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-77-9P, 3-[2-[4-(Methanesulfonyl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-78-0P, 3-[2-[4-(Methanesulfonyl)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-79-1P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-(methylsulfonyl)phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-80-4P, 3-[2-[4-(Acetyl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-81-5P, 3-[2-[4-(Methylcarbonylamino)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-82-6P, 3-[2-[4-(Methylcarbonylamino)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-

yl)imidazo[1,2-a]pyridine 656239-84-8P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-aminophenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-85-9P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(trifluoromethylsulfonyl)amino]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-86-0P, 3-[2-[4-(Morpholin-4-yl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-87-1P, 3-[2-[4-(4-Methylpiperazin-1-yl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-88-2P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-89-3P, 3-[2-[4-(Morpholin-4-yl)methyl]phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-93-9P, 6-Chloro-2-(6-methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-94-0P***, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine ***656239-95-1P, 6-Chloro-2-(6-methylpyridin-2-yl)-3-[2-[4-[(pyrrolidin-1-yl)methyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-96-2P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-97-3P 656239-98-4P, 3-[2-[4-[(Tetrahydropyran-4-yl)amino]carbonyl]phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-99-5P, 3-[2-[4-[(Tetrahydropyran-4-yl)amino]carbonyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-01-6P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-02-7P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(3-methoxypropylamino)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-03-8P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-04-9P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(1-ethylpiperazin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-05-0P, 2-(6-Fluoropyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-06-1P, 2-(Pyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-07-2P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[2-(dimethylamino)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-10-7P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-11-8P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-12-9P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-13-0P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(1-methylimidazol-4-yl)methyloxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-14-1P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(1-methylimidazol-4-yl)methyloxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-15-2P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[[[aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-16-3P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[[[aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-17-4P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-(morpholin-4-yl)phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-18-5P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-(morpholin-4-yl)phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


11783251

(Uses)

(inhibitor of TGF- β signaling pathway; preparation of imidazopyridines as inhibitors of transforming growth factor-beta (TGF- β) signaling pathway)


RN 656239-73-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-74-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-75-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(trifluoromethoxy)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-76-8 CAPLUS


CN Benzonitrile, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-77-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-78-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-79-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-80-4 CAPLUS


CN Ethanone, 1-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-81-5 CAPLUS

CN Acetamide, N-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-82-6 CAPLUS

CN Acetamide, N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 656239-84-8 CAPLUS


CN Benzenamine, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-85-9 CAPLUS


CN Methanesulfonamide, 1,1,1-trifluoro-N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-86-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-87-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-88-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-89-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 656239-93-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-94-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-95-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-96-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

11783251



RN 656239-97-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 656239-98-4 CAPLUS

CN Benzamide, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 656239-99-5 CAPLUS


CN Benzamide, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



11783251


RN 656240-01-6 CAPLUS

CN Morpholine, 4-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-02-7 CAPLUS

CN Benzamide, N-(3-methoxypropyl)-4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-03-8 CAPLUS

CN Morpholine, 4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 656240-04-9 CAPLUS


CN Piperazine, 1-ethyl-4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 656240-05-0 CAPLUS


11783251

CN Morpholine, 4-[4-[4-[2-(6-fluoro-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-06-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-07-2 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 656240-10-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-11-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(4-


11783251

morpholinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-12-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-13-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-3-[2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656240-14-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



11783251


RN 656240-15-2 CAPLUS

CN Acetamide, 2-[4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-16-3 CAPLUS

CN Acetamide, 2-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-17-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656240-18-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




IT 656239-45-1P, 3-(2-Bromopyridin-4-yl)-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-46-2P, 3-(2-Bromopyridin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-49-5P, 3-(2-Bromopyridin-4-yl)-6-chloro-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-50-8P, 3-(2-Bromopyridin-4-yl)-7-methyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-51-9P, 3-(2-Bromopyridin-4-yl)-8-methyl-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-53-1P, 3-(2-Bromopyridin-4-yl)-2-(6-fluoropyridin-2-yl)imidazo[1,2-a]pyridine 656239-54-2P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-55-3P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-58-6P, 6-Chloro-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-59-7P, 7-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-60-0P, 8-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-61-1P, 3-[2-[4-(Carboxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-62-2P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-63-3P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-65-5P, 8-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-66-6P, 7-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-67-7P, 3-[2-(4-Bromophenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-68-8P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-69-9P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-71-3P, 7-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-72-4P, 8-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazopyridines as inhibitors of transforming growth factor-beta (TGF- β) signaling pathway)

RN 656239-45-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-46-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 656239-49-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-6-chloro-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-50-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-7-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-51-9 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-8-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-53-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-2-(6-fluoro-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 656239-54-2 CAPLUS

CN Benzaldehyde, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-55-3 CAPLUS

CN Benzaldehyde, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-58-6 CAPLUS


CN Benzaldehyde, 4-[4-[6-chloro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-59-7 CAPLUS


CN Benzaldehyde, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-60-0 CAPLUS

CN Benzaldehyde, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-61-1 CAPLUS

CN Benzoic acid, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-62-2 CAPLUS


CN Phenol, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-63-3 CAPLUS


CN Phenol, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-65-5 CAPLUS

CN Phenol, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-66-6 CAPLUS

CN Phenol, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-67-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-(4-bromophenyl)-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-68-8 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 656239-69-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-71-3 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-7-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-72-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-8-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = CH or N; R1 = H, alk(en/yn)yl, perfluoro/alkoxy, halo, CN, perfluoroalkyl, NH2 and derivs., (CH2)nNH2 and derivs., CONH2 and derivs., SO2H and derivs., SO2NH2 and derivs., etc.; R2 = H, alkyl, halo, CN, perfluoroalkyl; R3 = H, halo; R4 = H, halo, alkyl, NH2 and derivs.; n = 1-4] were prepared as inhibitors of the transforming growth factor-beta (TGF- β) signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF- β type I or activin-like kinase-5 (ALK-5) receptor for treatment and prevention of a disease state mediated by this pathway. For example, II was prepared in 3 steps by reaction of 2-bromo-4-methylpyridine with 6-methylpicolinic acid Me ester, cyclocondensation of ethanone with 2-aminopyridine, and Pd-cross coupling of III with 4-(methanesulfonyl)phenylboronic acid. II showed an ALK5 receptor modulator activity of 11 nM in an ALK5 fluorescence polarization assay and TGF- β cellular activity of 125 nM in a cellular transcriptional assay. Thus, I are useful for treating or preventing a disease or condition mediated by ALK-5 inhibition, in particular kidney fibrosis.

11783251

L11 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:120851 CAPLUS

DOCUMENT NUMBER: 140:181331

TITLE: Preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders

INVENTOR(S): Dodic, Nerina; Gellibert, Francoise Jeanne

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 119 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013135	A1	20040212	WO 2003-EP8496	20030729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003260345	A1	20040223	AU 2003-260345	20030729
EP 1539748	A1	20050615	EP 2003-766385	20030729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005539000	T	20051222	JP 2004-525405	20030729
US 2005245520	A1	20051103	US 2005-522969	20050131
PRIORITY APPLN. INFO.:			GB 2002-17751	A 20020731
			GB 2003-14698	A 20030624
			WO 2003-EP8496	W 20030729

OTHER SOURCE(S): MARPAT 140:181331

IT 656239-82-6P, 3-[2-[4-(Acetylamino)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-84-8P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-aminophenyl)pyridin-4-yl]imidazo[1,2-a]pyridine


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders)


RN 656239-82-6 CAPLUS

CN Acetamide, N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)

11783251



RN 656239-84-8 CAPLUS
CN Benzenamine, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 656239-73-5P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-74-6P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-75-7P, 3-[2-[4-(Trifluoromethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-76-8P, 3-[2-(4-Cyanophenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-77-9P, 3-[2-[4-(Methylsulfonyl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-78-0P, 3-[2-[4-(Methylsulfonyl)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-79-1P, 8-Methyl-3-[2-[4-(methylsulfonyl)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-80-4P, 3-[2-(4-Acetylphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-81-5P, 3-[2-[4-(Acetyl amino)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-85-9P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(trifluoromethylsulfonyl)amino]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-86-0P, 3-[2-[4-(Morpholin-4-yl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-87-1P, 3-[2-[4-(4-Methylpiperazin-1-yl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-88-2P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-89-3P, 3-[2-[4-[(Morpholin-4-yl)methyl]phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-93-9P, 6-Chloro-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-94-0P, 7-Methyl-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-95-1P, 6-Chloro-3-[2-[4-[(pyrrolidin-1-yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-96-2P, 8-Methyl-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-98-4P, 3-[2-[4-[(Tetrahydropyran-4-yl)amino]carbonyl]phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-99-5P,


3-[2-[4-[(Tetrahydropyran-4-yl)amino]carbonyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-01-6P,
 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-02-7P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(3-methoxypropylamino)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-03-8P, 8-Methyl-3-[2-[4-[(morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-04-9P, 8-Methyl-3-[2-[4-[(4-ethylpiperazin-1-yl)carbonyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-05-0P, 3-[2-[4-[(Morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]-2-(6-fluoropyridin-2-yl)imidazo[1,2-a]pyridine 656240-06-1P, 2-(Pyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-13-0P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(1-methylimidazol-4-yl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-14-1P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(1-methylimidazol-4-yl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-15-2P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-16-3P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-17-4P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-(morpholin-4-yl)phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-18-5P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-(morpholin-4-yl)phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 657399-23-0P, 8-Methyl-3-[2-[4-[(pyrrolidin-1-yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders)

RN 656239-73-5 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-74-6 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 656239-75-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(trifluoromethoxy)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-76-8 CAPLUS

CN Benzonitrile, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-77-9 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-78-0 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-79-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-80-4 CAPLUS

CN Ethanone, 1-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 656239-81-5 CAPLUS


CN Acetamide, N-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 656239-85-9 CAPLUS


CN Methanesulfonamide, 1,1,1-trifluoro-N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-86-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-87-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-88-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-89-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 656239-93-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-94-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-95-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-96-2 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-98-4 CAPLUS

CN Benzamide, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 656239-99-5 CAPLUS

CN Benzamide, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 656240-01-6 CAPLUS


CN Morpholine, 4-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 656240-02-7 CAPLUS


CN Benzamide, N-(3-methoxypropyl)-4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656240-03-8 CAPLUS

CN Morpholine, 4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-04-9 CAPLUS

CN Piperazine, 1-ethyl-4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 656240-05-0 CAPLUS


CN Morpholine, 4-[4-[4-[2-(6-fluoro-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 656240-06-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 2-(2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656240-13-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-3-[2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656240-14-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656240-15-2 CAPLUS


CN Acetamide, 2-[4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 656240-16-3 CAPLUS


11783251

CN Acetamide, 2-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-17-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-18-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 657399-23-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



IT 656240-07-2P, 3-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-10-7P,

11783251

7-Methyl-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-11-8P,

7-Methyl-3-[2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-12-9P,


8-Methyl-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders)


RN 656240-07-2 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-10-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-11-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656240-12-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



IT 656239-45-1P, 3-(2-Bromopyridin-4-yl)-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-46-2P, 3-(2-Bromopyridin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-49-5P, 6-Chloro-3-(2-bromopyridin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-50-8P, 7-Methyl-3-(2-bromopyridin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-51-9P, 8-Methyl-3-(2-bromopyridin-4-yl)-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-53-1P, 3-(2-Bromopyridin-4-yl)-2-(6-fluoropyridin-2-yl)imidazo[1,2-a]pyridine 656239-54-2P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-55-3P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-58-6P, 6-Chloro-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-59-7P, 7-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-60-0P, 8-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-61-1P, 3-[2-(4-Carboxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-62-2P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-63-3P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-65-5P, 8-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-66-6P, 7-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-67-7P, 3-[2-(4-Bromophenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-68-8P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-69-9P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-71-3P, 7-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-72-4P, 8-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders)

RN 656239-45-1 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-2-(2-pyridinyl)- (9CI)
(CA INDEX NAME)

11783251




RN 656239-46-2 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 656239-49-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-6-chloro-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 656239-50-8 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-7-methyl-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 656239-51-9 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-8-methyl-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)

11783251




RN 656239-53-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-(2-bromo-4-pyridinyl)-2-(6-fluoro-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 656239-54-2 CAPLUS

CN Benzaldehyde, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-55-3 CAPLUS


CN Benzaldehyde, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-58-6 CAPLUS


CN Benzaldehyde, 4-[4-[6-chloro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-59-7 CAPLUS

CN Benzaldehyde, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-60-0 CAPLUS

CN Benzaldehyde, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-61-1 CAPLUS


CN Benzoic acid, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-62-2 CAPLUS


CN Phenol, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

11783251




RN 656239-63-3 CAPLUS

CN Phenol, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-65-5 CAPLUS

CN Phenol, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-66-6 CAPLUS


CN Phenol, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-67-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-(4-bromophenyl)-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251




RN 656239-68-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-69-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-71-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-7-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)





RN 656239-72-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-8-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

11783251



GI



AB This invention relates to novel 2-phenylpyridin-4-yl heterocycles (shown as I; variables defined below; e.g. II) that are inhibitors of the transforming growth factor, ('TGF')- β signaling pathway, in particular, the phosphorylation of Smad-2 or Smad-3 by the TGF- β type I or activin-like kinase ('ALK')-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway, e.g. fibrosis (no data). All examples of I show ALK-5 receptor modulator activity (having IC₅₀ values at 0.4-275 nM) and TGF- β cellular activity (having IC₅₀ values at 0.001-10 μ M). 4-[4-[4-[2-tert-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]pyridin-2-yl]phenyl]morpholine showed an ALK-5 receptor modulator activity of 34 nM and TGF- β cellular activity of 183 nM. N-(tetrahydropyran-4-yl)-4-[4-[2-isopropyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]pyridin-2-yl]benzamide showed an ALK-5 receptor modulator activity of 25 nM and TGF- β cellular activity of <14 nM. Although the methods of preparation are not claimed, >150 example preps. of I and .apprx.130 example preps. of intermediates are included. For example, II

was prepared in 37% yield by reacting 4-[4-[3-(6-methylpyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]pyridin-2-yl]phenol and NaH in DMF with 1-methyl-4-hydroxymethylimidazole followed by removal of the trityl group using HCl in MeOH; details are also given for preparation of the reactants. For I: A is furan, dioxolane, thiophene, pyrrole, imidazole, pyrrolidine, pyran, pyridine, pyrimidine, morpholine, piperidine, oxazole, isoxazole, oxazoline, oxazolidine, thiazole, isothiazole, thiadiazole, benzofuran, indole, isoindole, indazole, imidazopyridine, quinazoline, quinoline, isoquinoline, pyrazole or triazole; X is N or CH; R1 is H, C1-6alkyl, C1-6alkenyl, C1-6alkoxy, halo, cyano, perfluoro C1-6alkyl, perfluoroC1-6alkoxy, -NR5R6, -(CH2)nNR5R6, -O(CH2)nOR7, -O(CH2)n-Het, -O(CH2)nNR5R6, -CONR5R6, -CO(CH2)nNR5R6, -SO2R7, -SO2NR5R6, -NR5SO2R7, -NR5COR7, -O(CH2)nCONR5R6, -NR5CO(CH2)nNR5R6 or -C(O)R7; R2 is H, C1-6alkyl, halo, cyano or perfluoroC1-6alkyl; R3 is H or halo; R4 is H, halo, Ph, C1-6alkyl or -NR5R6; addnl. details including provisos are given in the claims.

11783251

L11 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:932827 CAPLUS

DOCUMENT NUMBER: 136:61303

TITLE: Organic electroluminescent devices using condensed heterocyclic rings

INVENTOR(S): Taguchi, Toshiki; Mishima, Masayuki; Ise, Toshihiro; Okada, Hisashi

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001357977	A	20011226	JP 2000-175981	20000612
PRIORITY APPLN. INFO.:			JP 2000-175981	20000612

OTHER SOURCE(S): MARPAT 136:61303

IT 382617-91-6P


RL: DEV (Device component use); SPN (Synthetic preparation); PREP

(Preparation); USES (Uses)


(organic electroluminescent devices using condensed heterocyclic rings)

RN 382617-91-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-phenyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



GI



AB The invention relates to an organic electroluminescent device comprising a pair of electrodes sandwiching ≥ 1 layer(s) containing ≥ 1 condensed heterocyclic compds. represented by I (X = C, N; Z1 and Z2 may form a N-containing heterocyclyl) and ortho metal (Ir) complexes. The device shows high luminance, luminescent efficiency, and superior in durability.

11783251

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	54.11	574.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.80	-7.80

STN INTERNATIONAL LOGOFF AT 18:56:33 ON 11 JAN 2007